Abstract：
OBJECTIVE: Various studies have demonstrated the causal relationship between gut microbiota and efficacy of chemotherapy; however, the impact of gut microbiota on breast cancer has not been fully elucidated. This study aimed to evaluate the associations between the gut microbiota before neoadjuvant chemotherapy and its consequent efficacy in breast cancer.
METHODS: This prospective observational study included patients who received neoadjuvant chemotherapy for primary early breast cancer at eight institutions between October 1, 2019, and March 31, 2022. We performed 16S rRNA analysis of fecal samples and α and β diversity analyses of the gut microbiota. The primary endpoint was the association between the gut microbiota and pathological complete response (pCR) to neoadjuvant chemotherapy.
RESULTS: Among the 183 patients, the pCR rate after neoadjuvant chemotherapy was 36.1% in all patients and 12.9% (9/70), 69.5% (41/59), and 29.6% (16/54) in those with the luminal, human epidermal growth factor receptor 2, and triple-negative types, respectively. The α diversity of the gut microbiota did not significantly differ between patients with pCR and those without pCR. Among the gut microbiota, two species (Victivallales, P = 0.001 and Anaerolineales, P = 0.001) were associated with pCR, and one (Gemellales, P = 0.002) was associated with non-pCR.
CONCLUSIONS: Three species in the gut microbiota had potential associations with neoadjuvant chemotherapy efficacy, but the diversity of the gut microbiota was not associated with response to chemotherapy. Further research is needed to validate our findings.
METHODS: This prospective observational study included patients who received neoadjuvant chemotherapy for primary early breast cancer at eight institutions between October 1, 2019, and March 31, 2022. We performed 16S rRNA analysis of fecal samples and α and β diversity analyses of the gut microbiota. The primary endpoint was the association between the gut microbiota and pathological complete response (pCR) to neoadjuvant chemotherapy.
RESULTS: Among the 183 patients, the pCR rate after neoadjuvant chemotherapy was 36.1% in all patients and 12.9% (9/70), 69.5% (41/59), and 29.6% (16/54) in those with the luminal, human epidermal growth factor receptor 2, and triple-negative types, respectively. The α diversity of the gut microbiota did not significantly differ between patients with pCR and those without pCR. Among the gut microbiota, two species (Victivallales, P = 0.001 and Anaerolineales, P = 0.001) were associated with pCR, and one (Gemellales, P = 0.002) was associated with non-pCR.
CONCLUSIONS: Three species in the gut microbiota had potential associations with neoadjuvant chemotherapy efficacy, but the diversity of the gut microbiota was not associated with response to chemotherapy. Further research is needed to validate our findings.
摘要：
目的：各种研究证明了肠道菌群与化疗疗效之间的因果关系；然而，肠道菌群对乳腺癌的影响尚未完全阐明.本研究旨在评估乳腺癌新辅助化疗前肠道菌群与其后续疗效之间的关系。
方法：这项前瞻性观察性研究包括2019年10月1日至2022年3月31日在8个机构接受新辅助化疗治疗原发性早期乳腺癌的患者。我们对粪便样本进行了16SrRNA分析，并对肠道微生物群进行了α和β多样性分析。主要终点是肠道菌群与新辅助化疗的病理完全缓解(pCR)之间的关联。
结果：在183名患者中，所有患者新辅助化疗后的pCR率为36.1%，12.9%(9/70)，69.5%（41/59），和29.6％（16/54）在那些与腔，人表皮生长因子受体2和三阴性类型，分别。pCR患者和无pCR患者的肠道微生物群的α多样性没有显着差异。在肠道微生物群中，两种（Victivallales，P=0.001和Anaerolineales，P=0.001）与pCR相关，和一个（Gemellales，P=0.002）与非pCR相关。
结论：三种肠道菌群与新辅助化疗疗效有潜在关联，但是肠道微生物群的多样性与化疗的反应无关。需要进一步的研究来验证我们的发现。
方法：这项前瞻性观察性研究包括2019年10月1日至2022年3月31日在8个机构接受新辅助化疗治疗原发性早期乳腺癌的患者。我们对粪便样本进行了16SrRNA分析，并对肠道微生物群进行了α和β多样性分析。主要终点是肠道菌群与新辅助化疗的病理完全缓解(pCR)之间的关联。
结果：在183名患者中，所有患者新辅助化疗后的pCR率为36.1%，12.9%(9/70)，69.5%（41/59），和29.6％（16/54）在那些与腔，人表皮生长因子受体2和三阴性类型，分别。pCR患者和无pCR患者的肠道微生物群的α多样性没有显着差异。在肠道微生物群中，两种（Victivallales，P=0.001和Anaerolineales，P=0.001）与pCR相关，和一个（Gemellales，P=0.002）与非pCR相关。
结论：三种肠道菌群与新辅助化疗疗效有潜在关联，但是肠道微生物群的多样性与化疗的反应无关。需要进一步的研究来验证我们的发现。
